Welcome to our dedicated page for Resverlogix news (Ticker: RVXCF), a resource for investors and traders seeking the latest updates and insights on Resverlogix stock.
Resverlogix Corp (RVXCF) generates news that reflects its role as a Calgary-based late-stage biotechnology company focused on epigenetic therapies for chronic disease. Company announcements frequently center on the development of its lead candidate apabetalone (RVX-208), a BD2-selective BET inhibitor that Resverlogix is advancing for cardiovascular disease, associated comorbidities, and post COVID-19 conditions.
Investors following RVXCF-related news can expect updates on clinical and scientific milestones, including publications and conference presentations. Resverlogix regularly highlights peer-reviewed articles on apabetalone’s potential in cardiovascular disease, diabetes, chronic kidney disease, vascular cognitive impairment, pulmonary arterial hypertension, and rare diseases such as facioscapulohumeral muscular dystrophy and Fabry disease. The company also reports on independent research groups presenting data on apabetalone’s cardioprotective and other biological effects.
Corporate governance and financing developments are another recurring theme. News releases cover annual and special meetings of shareholders, director elections, changes to the board of directors, and details of secured debenture arrangements and extensions with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. These items provide context on how the company manages its capital structure and oversight.
Resverlogix’s partnership with EVERSANA, which supports the planned commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States, also features in its communications. For readers tracking RVXCF, this news page offers a centralized view of scientific progress, clinical program updates, governance decisions, and key financial agreements disclosed by the company.
Resverlogix (OTC:RVXCF) announced the Alberta Securities Commission issued a management cease trade order (MCTO) after the company missed the March 31, 2026 filing deadline for its 2025 annual audited financial statements, AIF, and MD&A.
The MCTO bars the CEO and CFO from trading until the Annual Filings are filed and the order is revoked or varied; public trading of listed common shares continues. The company and its auditor expect to complete the audit by April 10, 2026 but cannot assure timing.
Resverlogix (OTC: RVXCF) provided a bi-weekly update on its MCTO application with the Alberta Securities Commission after missing the March 31, 2026 filing deadline for its annual audited financial statements and related filings.
The company attributes the Default to initial audit start delays, says it is working with its auditor, and expects completion by April 10, 2026 but offers no assurance. CEO/CFO trading would be restricted if an MCTO is granted; public trading would continue.
Resverlogix (OTC: RVXCF) announced a delay in filing its Annual Audited Financial Statements, AIF, and MD&A for year ended December 31, 2025 because its auditor anticipates not completing the audit by the March 31, 2026 deadline.
The company applied to the Alberta Securities Commission for a management cease trade order (MCTO), expects (but cannot assure) filings by April 10, 2026, will provide bi-weekly status reports under NP 12-203, and has imposed an insider trading blackout.
Resverlogix (RVXCF) announced on November 18, 2025 the appointment of Bradley Glass, J.D. to its board of directors.
Mr. Glass joins the board with four years as General Counsel at Hepalink USA, where he managed U.S. legal matters, and over 20 years in private law practice representing clients in federal, state and local courts and administrative tribunals. He holds degrees from Wabash College and Indiana University School of Law.
The company's chairman and CEO said Glass will add legal and business experience to the board, and Glass said he looks forward to supporting Resverlogix and the development of apabetalone.
Resverlogix Corp. (TSX: RVX, OTC: RVXCF) held its Annual Meeting of Shareholders on June 30, 2025, in Calgary, Alberta. During the meeting, shareholders elected four Board members with strong approval rates ranging from 96.55% to 97.11%.
The elected Board members include Donald J. McCaffrey (96.55% approval), Kelly McNeill (96.79% approval), Siu Lun To (97.11% approval), and Kenneth Zuerblis (96.94% approval). All resolutions outlined in the May 16, 2025 Notice of Meeting and Management Information Circular were approved by shareholders.
Resverlogix Corp. (TSX: RVX) presented at the European Society of Cardiology (ESC) Congress 2024, highlighting apabetalone's potential cardioprotective benefits. Key points include:
1. Apabetalone reduced MACE and heart failure hospitalization hazard by 63% (p=0.0002) in patients taking next-generation glucose-lowering drugs.
2. Independent researchers presented data on apabetalone's benefits for vascular dysfunction, heart failure, cellular aging, and pulmonary arterial hypertension.
3. The company positions apabetalone as a drug with potential benefits across various metabolic diseases, including cardiovascular disease, chronic kidney disease, inflammation, and diabetes.
4. Resverlogix plans to demonstrate apabetalone's efficacy in combination with SGLT2 inhibitors in the upcoming BETonMACE2 trial.
Resverlogix Corp. (TSX: RVX) held its Annual & Special Meeting of Shareholders on July 31, 2024, in Calgary, Alberta. Shareholders elected four Board members and approved all resolutions outlined in the Notice of Meeting and Management Information Circular. The voting results showed strong support for all directors, with approval rates ranging from 95.11% to 95.91%.
Additionally, Resverlogix announced the closing of a two-year extension of its US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., This extension provides the company with continued financial stability. The Information Circular is available on SEDAR and the Resverlogix website, and a webcast archive of the executive presentation is accessible online.
Resverlogix Corp. (TSX: RVX) has announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., The maturity date has been extended to May 13, 2026. Key changes include:
1. Elimination of Hepalink's conversion privileges
2. Increase in interest rate from 12% to 18% per annum, effective May 14, 2024
3. Additional reporting requirements for Resverlogix
4. Continuation of normal business operations
The amendment is subject to Toronto Stock Exchange and shareholder approval. Shareholders will vote on the amendments at Resverlogix's annual and special meeting on July 31, 2024. Hepalink has agreed to forbear from enforcing the debenture, contingent on shareholder approval.
Resverlogix has rescheduled its Annual and Special Meeting of Shareholders to July 31, 2024, at 1:00 PM MT, from its original date of June 27, 2024. Shareholders will receive a Notice of Meeting and Management Information Circular detailing the matters to be discussed. These documents will also be available on SEDAR+ at www.sedarplus.ca. Following the formal business proceedings, Resverlogix will present a corporate update.
Resverlogix Corp. (TSX: RVX) announced a two-year extension of its US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group. The new maturity date is May 13, 2026.
Along with the extension, Hepalink's conversion privileges have been eliminated, and the interest rate has increased from 12% to 18% per annum, starting May 14, 2024. The changes are subject to execution of definitive transaction documents, customary closing conditions, and Toronto Stock Exchange approval.
CEO Donald McCaffrey expressed appreciation for Hepalink's continued support.